reference/432984

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/432984

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Comparative Study\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	308
issn	1470-2045
issueIdentifier	3
pageRange	300-308
publicationName	The Lancet. Oncology
startingPage	300
bibliographicCitation	Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012 Mar;13(3):300–8. doi: 10.1016/s1470-2045(11)70385-0. PMID: 22277837.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb65de5faed4a3caa1ba153349afaba3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f41844c8c02a540a321bd4a991e38d6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5fd59d3feeb10584d1f2fd3f8bae9dc7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d1a9c0ce6d9bada28c47bab69ba2e3b4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d10291502d03181a38a3e8a6877e6bf1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_738602bbc190cb1e1144f571bdaa2c27 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c29c8546fca087e0433e1e03607885f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31447b8bb72edee56b1c7a1dd33a77cd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c3b536d30628a991b50f27e7cc8d64a5
date	201203
identifier	https://doi.org/10.1016/s1470-2045%2811%2970385-0 https://pubmed.ncbi.nlm.nih.gov/22277837
isPartOf	https://portal.issn.org/resource/ISSN/1470-2045 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
discusses	http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0184558 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0500817 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0593322 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0493669 http://id.nlm.nih.gov/mesh/M0018336 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0443608
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D047428Q000627 http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D011799Q000627 http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D000971Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D006147Q000031 http://id.nlm.nih.gov/mesh/D002289Q000201 http://id.nlm.nih.gov/mesh/D000077143 http://id.nlm.nih.gov/mesh/D011446 http://id.nlm.nih.gov/mesh/D047428Q000009 http://id.nlm.nih.gov/mesh/D043823Q000008 http://id.nlm.nih.gov/mesh/D002289Q000556 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D016009 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D016879 http://id.nlm.nih.gov/mesh/D005971Q000008 http://id.nlm.nih.gov/mesh/D008175Q000473 http://id.nlm.nih.gov/mesh/D000068437 http://id.nlm.nih.gov/mesh/D000069347 http://id.nlm.nih.gov/mesh/D006147Q000008 http://id.nlm.nih.gov/mesh/D011799Q000009 http://id.nlm.nih.gov/mesh/D057239 http://id.nlm.nih.gov/mesh/D008175Q000201 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D066246Q000378 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D005060 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D066246Q000037 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D007150 http://id.nlm.nih.gov/mesh/D013997 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000970Q000009
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176871 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7507 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44263854 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID176870 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6847 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127377427 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129683629 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129159660 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851

Total number of triples: 93.